Dupilumab
DAIT ADRN-09
Approved small_molecule terminated
Quick answer
Dupilumab for Atopic Dermatitis (AD) is a Approved program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Atopic Dermatitis (AD)
- Phase
- Approved
- Modality
- small_molecule
- Status
- terminated